# A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

Source: https://onco.cc/trials/nct05526755/  
OnCo record `nct05526755` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Osimertinib in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.

## Summary

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) is a phase 2 interventional study registered as NCT05526755 by AstraZeneca, with 188 participants enrolled, started 2023-03-06 and due to reach its primary completion in 2029-11-22. Interventions recorded: Osimertinib 80 mg/40 mg.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05526755
- Phase: 2
- Setting: An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants With EGFRm-positive Stage II-IIIB NSCLC, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
- Sponsor: AstraZeneca
- Enrolled: 188

## Sources

- ClinicalTrials.gov NCT05526755: https://clinicaltrials.gov/study/NCT05526755

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05526755.json